<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636568</url>
  </required_header>
  <id_info>
    <org_study_id>16-05023</org_study_id>
    <nct_id>NCT03636568</nct_id>
  </id_info>
  <brief_title>Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)</brief_title>
  <acronym>DHAPS</acronym>
  <official_title>Early Fluid Restriction to Prevent Delayed Hyponatremia Following Pituitary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hyponatremia is defined as sodium below the normal range of 135-145. Symptomatically, it can&#xD;
      cause patients to experience a wide range of symptoms including lethargy, headache, nausea,&#xD;
      vomiting and in severe cases coma and even death. The goal of this study is to prospectively&#xD;
      compare two approaches to the postoperative fluid management of patients undergoing&#xD;
      transsphenoidal resection of a pituitary tumor or cyst to decrease the occurrence of&#xD;
      postoperative delayed hyponatremia. One group will be placed on moderate fluid restriction&#xD;
      and the other group will be placed on ad lib fluid intake.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Any adult patient with a pituitary adenoma (either non-functioning, prolactin-secreting,&#xD;
      growth hormone secreting, gonadotropin secreting, or TSH (thyroid stimulating hormone)&#xD;
      secreting) or cyst scheduled to undergo transsphenoidal resection will be included in the&#xD;
      study. Patients with chronic hyponatremia will be excluded.&#xD;
&#xD;
      Patients will be randomly assigned to one of two groups:&#xD;
&#xD;
      Group 1: these patients will be treated with moderate fluid restriction (1000 ml/24 hours for&#xD;
      patients &lt;100kg and 1200 ml of fluid/24 hours for &gt;100 kg starting on postoperative day 1.&#xD;
      Fluid restriction will be aborted if diabetes insipidus occurs. Diabetes insipidus occurs if&#xD;
      a patient does not produce enough ADH (anti-diuretic hormone) which is needed to concentrate&#xD;
      the urine. Diabetes insipidus causes increased urination and increased thirst and can cause&#xD;
      hypernatremia (an increased sodium level). A person will be diagnosed with diabetes insipidus&#xD;
      if they meet all of the following criteria: serum sodium level &gt; 146, dilute urine with a&#xD;
      urine specific gravity &lt; 1.003 and increased urine output defined by urine output &gt;&#xD;
      300cc/hour for 2 consecutive hours( or &gt; 6 liter/24 hours).&#xD;
&#xD;
      Group 2: these patients will not be placed on fluid restriction, they will be allowed to&#xD;
      drink water freely after surgery.&#xD;
&#xD;
      All patients will be started on D5 ½ normal saline IV fluids (Weight based) and will be&#xD;
      allowed to eat and drink starting on POD 1.&#xD;
&#xD;
      All the patients will receive a thirst questionnaire that will be completed daily starting on&#xD;
      POD 1 until POD 13. The intensity of thirst will be assessed on a scale of 1--10, with 1&#xD;
      being no thirst, 5 being normal thirst and 10 being unbearable thirst.&#xD;
&#xD;
      Patients will have basic metabolic panels checked on post-surgical days 1, 3, 7, 10 and 13.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of hyponatremia or low sodium</measure>
    <time_frame>3-14 days after surgery</time_frame>
    <description>Sodium level &lt;135 mEq/L</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyponatremia</condition>
  <condition>Hyponatremic</condition>
  <condition>Pituitary Tumor</condition>
  <condition>Pituitary</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Fluid restricted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh &lt;=100 kg and 1200 cc/24 hours for patients who weigh &gt; 100kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Fluid Restricted</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No fluid restriction</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid Restricted Group</intervention_name>
    <description>Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients &lt; 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients &gt;100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh &lt;=100 kg and 1200 cc/24 hours for patients who weigh &gt; 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:&#xD;
Serum Na level must be &lt; 145 mEq/l&#xD;
Patient should be taking fluids by mouth&#xD;
Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated.</description>
    <arm_group_label>Fluid restricted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Any adult patient with a pituitary adenoma or cyst (either non-functioning,&#xD;
        prolactin-secreting, growth hormone secreting, ACTH (adrenocorticotropic&#xD;
        hormone)-secreting, gonadotropin secreting, or TSH secreting) scheduled to undergo&#xD;
        pituitary resection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of chronic hyponatremia&#xD;
&#xD;
          -  Patients with a history of SIADH (syndrome of inappropriate antidiuretic hormone) ,&#xD;
             except if secondary to hypothyroidism or adrenal insufficiency, or in association with&#xD;
             prior TSS&#xD;
&#xD;
          -  Patients with diabetes insipidus or patients receiving DDAVP&#xD;
&#xD;
          -  Patients without an intact thirst mechanism&#xD;
&#xD;
          -  Patients with CKD (chronic kidney disease) stage III, IV or V&#xD;
&#xD;
          -  Patients with untreated adrenal insufficiency or hypothyroidism&#xD;
&#xD;
          -  Patients with class III or IV heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Silverstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Traci Bell, BSN</last_name>
    <phone>314-747-5371</phone>
    <email>traci.bell@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Silverstein, MD</last_name>
    <phone>314-747-7006</phone>
    <email>jsilverstein@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Bell, BSN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyponatremia</keyword>
  <keyword>hyponatremic</keyword>
  <keyword>pituitary tumor</keyword>
  <keyword>transsphenoidal resection</keyword>
  <keyword>pituitary surgery</keyword>
  <keyword>pituitary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

